Q-omics provides the consensus-scored SNORA9B profile across patient tissues and cancer cell-line models. SNORA9B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNORA9B is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, SNORA9B RNA expression shows 15,607 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, BLCA, and UVM as cancer lineages where SNORA9B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA9B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA9B survival associations across molecular data types. SNORA9B RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA9B RNA expression–survival associations across cancer types. High SNORA9B expression shows unfavorable associations in KIRC, UVM, KIRP, SARC, STAD and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SNORA9B RNA expression.
This table summarizes SNORA9B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA9B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA9B shows higher tumor expression in BLCA, STAD, COAD, LUSC, LIHC and CHOL. The BLCA box plot shows higher SNORA9B RNA expression in tumor versus normal tissue (log2 FC = +0.947, t-test p < 0.001).
This table shows molecular features associated with SNORA9B in patient tissues and cancer cell lines. In patient samples, SNORA9B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
